m2 Clinical cure can be achieved in some patients with acute myeloid leukemia. The concept of cure and the prognosis of different subgroups of patients are explained below. 1. AML is a malignant disease originating from hematopoietic stem cells. Some patients with m2 AML can achieve long-term survival after timely and effective treatment. Clinical cure is achieved if the patient has no relapse for more than 5 years after cure. Drugs include cytarabine, Zoerythromycin and so on. 2. If for m2 acute myeloid leukemia patients in the low-risk group, the survival period is longer, and generally only through chemotherapy and other methods can be controlled. In the case of m2 AML patients in the high-risk group, they are not sensitive to chemotherapy and have a shorter survival period, which can only be prolonged by treatment with bone marrow transplantation. Whether the disease can reach clinical cure is related to the patient’s physical quality, the stage of disease development, treatment methods and other factors, and should be standardized under the guidance of doctors.